Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
about
CIViC databaseDual kinase-bromodomain inhibitors for rationally designed polypharmacologyResistant mutations in CML and Ph(+)ALL - role of ponatinib.Secondary mutations as mediators of resistance to targeted therapy in leukemiaFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsTargeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsPolypharmacology in Precision Oncology: Current Applications and Future ProspectsInvestigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaBET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemiasThe Future of Targeting FLT3 Activation in AML.FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitorsThe MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.Overcoming AC220 resistance of FLT3-ITD by SAR302503.Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsFLT3 inhibitors: clinical potential in acute myeloid leukemia.Crenolanib is a selective type I pan-FLT3 inhibitorFLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.The role of quizartinib in the treatment of acute myeloid leukemia.Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?FLT3 inhibitors in AML: are we there yet?Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.Targeting FLT3 to treat leukemia.Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.Predicting Chemotherapy Resistance in AML.Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cellsBCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
P2860
Q27612411-80A9FA9F-1926-43FC-B397-343300972CD8Q27681935-788ECC79-BEC1-42B4-822E-39D5E6C2B579Q27853085-CB56F285-BBDE-48F2-9D48-CDD1438FD98CQ28087213-B4EA3E2C-E2A7-49AD-833B-3F230C51E272Q28289859-8D37EDE5-50B6-47D6-8A0C-8601CB4FD5E1Q28539032-D8316AEC-63B5-47FB-B263-51339E8FF9EAQ30846907-00269C13-AF25-4BBB-B6E7-AA4958AFC788Q33943277-053F4DF8-612F-42E9-BFB1-A9BC451B89C8Q34289202-ACDCF283-C97F-4FAE-84C6-F1F1008A142CQ34465221-5A0EF484-CDB5-47A1-AF1B-1876DA4E5F33Q34555386-3BE3E081-4603-416F-9B04-9ADC78CE520EQ34993145-7E4E99EF-3C25-4FFE-96BB-EBCCBD66DA64Q35016157-CC844AF7-EBB1-4B79-B7EF-A3D0B7BEDD69Q35576181-6D37BC17-4ED4-4572-BF90-E4EB8B0FF07EQ36362951-0C79532D-7AE3-40CB-875F-41951D616FADQ36865880-04C2866E-A467-45B0-B9A0-0E57D47F2BE0Q37148125-FAEDAD83-BD3B-4F64-8FDA-596757C0F886Q37334711-EC462053-4CEE-4AA5-8D28-1D94E73FF383Q37399091-F96A875A-09B4-484E-89F5-F6CA585D5A23Q37429734-9544B341-AB06-4E7E-8BE3-D2E3447FC1F4Q37638749-15969DD1-8AA8-44D0-8BF1-E9546C0136BAQ37701978-96A5C24A-01CD-4FFB-B2CD-0871609F5F08Q38101284-20D4BF78-0E77-4EDF-8FF2-9B0DD2AF48D4Q38144189-E979B136-0763-4C17-AD44-0E59D2735EB7Q38182335-DE2F5443-6B01-4EEF-9F1B-88D5A3EF1EA5Q38200564-921C1DAF-249A-46F8-809E-B130D984AC52Q38241988-7358E4D4-5D06-49EE-9E28-381B5BF38848Q38251339-4DE13918-7726-42C2-BB4F-EFD812A1370FQ38272140-E0B07CAD-45D4-4835-AB52-68EEEBE995EAQ38363058-25715C4C-2808-4F26-BF84-DB9F9AD607EAQ38381981-FE2EB256-EBEB-44E6-B3E3-418ADC0059CAQ38428692-10746BB0-A5F7-4539-B13E-2F06A3623743Q38664735-3C74193E-DBF3-4901-BB1E-8526AB2674B5Q38685553-E9D81A45-EFC3-4879-B423-3EF1EB95FA3EQ38713196-3766983E-98EE-4E69-BB2F-BF3690432A21Q39233284-5DAB2696-E65C-45FA-9BB5-B4CF60EBD5E2Q39252132-B6EFA59E-BBF3-43EF-96A6-82C0BF97DAA8Q40207115-6076AC9E-8C98-4B6A-BC1A-454B60840155Q40985734-D3E833BA-EA24-42AC-8F6A-BFFD16373D4AQ41980844-49007CCF-656E-409F-AAF3-429321C26715
P2860
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@ast
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@en
Activity of ponatinib against ...... se domain mutants of FLT3-ITD.
@nl
type
label
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@ast
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@en
Activity of ponatinib against ...... se domain mutants of FLT3-ITD.
@nl
altLabel
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@en
prefLabel
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@ast
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@en
Activity of ponatinib against ...... se domain mutants of FLT3-ITD.
@nl
P2093
P2860
P1433
P1476
Activity of ponatinib against ...... ase domain mutants of FLT3-ITD
@en
P2093
Catherine C Smith
Elisabeth A Lasater
Kimberly C Lin
Lauren E Damon
Neil P Shah
Sara Salerno
Whitney K Stewart
Xiaotian Zhu
P2860
P304
P356
10.1182/BLOOD-2012-07-442871
P407
P577
2013-04-18T00:00:00Z